(Q34566114)

3 August 2017

Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients (English)

1 reference

3 August 2017

0 references

Nicole M Kuderer

1

1 reference

3 August 2017

David C Dale

2

1 reference

3 August 2017

Jeffrey Crawford

3

1 reference

3 August 2017

Leon E Cosler

4

1 reference

3 August 2017

Gary H Lyman

5

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 May 2006

1 reference

3 August 2017

1 reference

3 August 2017

106

1 reference

3 August 2017

10

1 reference

3 August 2017

2258-2266

1 reference

Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial

3 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21847

The economics of febrile neutropenia: implications for the use of colony-stimulating factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21847

7 January 2021

2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21847

7 January 2021

2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21847

7 January 2021

Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21847

7 January 2021

Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: a review of the evidence

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21847

7 January 2021

Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21847

7 January 2021

Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21847

7 January 2021

Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21847

7 January 2021

Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21847

7 January 2021

Length of stay and mortality associated with febrile neutropenia among children with cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21847

7 January 2021

Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21847

7 January 2021

The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21847

7 January 2021

Prognostic factors influencing mortality in cancer patients with neutropenia and bacteremia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21847

7 January 2021

Clinical characteristics and therapeutic outcome of patients with febrile neutropenia who present in shock: need for better strategies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21847

7 January 2021

Impact of neutropenia duration on short-term mortality in neutropenic critically ill cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21847

7 January 2021

Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21847

7 January 2021

Bacteremic Pneumonia in Neutropenic Patients With Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21847

7 January 2021

Prognosis of infections in elderly patients with haematological diseases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21847

7 January 2021

Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21847

7 January 2021

Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21847

7 January 2021

Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21847

7 January 2021

Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21847

7 January 2021

Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21847

7 January 2021

Identifiers

DOI

10.1002/CNCR.21847

1 reference

3 August 2017

1 reference